JP3555620B2 - Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 - Google Patents
Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 Download PDFInfo
- Publication number
- JP3555620B2 JP3555620B2 JP2002571480A JP2002571480A JP3555620B2 JP 3555620 B2 JP3555620 B2 JP 3555620B2 JP 2002571480 A JP2002571480 A JP 2002571480A JP 2002571480 A JP2002571480 A JP 2002571480A JP 3555620 B2 JP3555620 B2 JP 3555620B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- isobutyl
- methanol
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC(C)c1c(*Cc2ccc(C(C)(CC)C=CC(CC)(CC)**)cc2*)cc(*(C)C)c(*)c1 Chemical compound CCC(C)c1c(*Cc2ccc(C(C)(CC)C=CC(CC)(CC)**)cc2*)cc(*(C)C)c(*)c1 0.000 description 3
- GXLPOJIULXFCOP-UHFFFAOYSA-N CC(C)(CN(c(cc(C)c(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O)O Chemical compound CC(C)(CN(c(cc(C)c(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O)O GXLPOJIULXFCOP-UHFFFAOYSA-N 0.000 description 1
- CIGNWBKXPVGMBM-PKNBQFBNSA-N CC(C)(CN(c(cc(CCC1)c1c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1nc(C)c[s]1)(=O)=O)O Chemical compound CC(C)(CN(c(cc(CCC1)c1c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1nc(C)c[s]1)(=O)=O)O CIGNWBKXPVGMBM-PKNBQFBNSA-N 0.000 description 1
- GOULACMCOJUVAF-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(C)c1)c1OCc(ccc(-c1nnn[nH]1)c1)c1Cl)S(c1cnccc1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc(ccc(-c1nnn[nH]1)c1)c1Cl)S(c1cnccc1)(=O)=O GOULACMCOJUVAF-UHFFFAOYSA-N 0.000 description 1
- ILTMQNRYNXMLNS-PKNBQFBNSA-N CC(C)CN(c(cc(C)c(C)c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1cccnc1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1cccnc1)(=O)=O ILTMQNRYNXMLNS-PKNBQFBNSA-N 0.000 description 1
- UAVCNMJTURISPB-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1ccc(C)[o]1)(=O)=O UAVCNMJTURISPB-UHFFFAOYSA-N 0.000 description 1
- LDGWZMWKZLCMJP-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(cc1)c(C)cc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(cc1)c(C)cc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O LDGWZMWKZLCMJP-UHFFFAOYSA-N 0.000 description 1
- DKPLGLFJMWXBKL-UHFFFAOYSA-N CC(C)CN(c(cc(C)cc1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)cc1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc[o]1)(=O)=O DKPLGLFJMWXBKL-UHFFFAOYSA-N 0.000 description 1
- DPYJVEIBKFKKGB-UHFFFAOYSA-N CC(C)CN(c(cc(c(C)c1)Cl)c1OCc(ccc(C(O)=O)c1)c1OC)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)CN(c(cc(c(C)c1)Cl)c1OCc(ccc(C(O)=O)c1)c1OC)S(c1nc(C)c[s]1)(=O)=O DPYJVEIBKFKKGB-UHFFFAOYSA-N 0.000 description 1
- XNXSFIMCKBGDMA-CSKARUKUSA-N CC(C)CN(c(cc(c(C)c1)Cl)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(c(C)c1)Cl)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1ccc(C)[o]1)(=O)=O XNXSFIMCKBGDMA-CSKARUKUSA-N 0.000 description 1
- TTWLHHPGUOJOJQ-UHFFFAOYSA-N CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc(cc1)ccc1C(N1)=NOC1=O)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc(cc1)ccc1C(N1)=NOC1=O)S(c1nc(C)c[s]1)(=O)=O TTWLHHPGUOJOJQ-UHFFFAOYSA-N 0.000 description 1
- VBPYYHZBHWQNKY-UXBLZVDNSA-N CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1nc(C)c[s]1)(=O)=O VBPYYHZBHWQNKY-UXBLZVDNSA-N 0.000 description 1
- UXTPWQNJKLFXSB-FMIVXFBMSA-N CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc(C)[o]1)(=O)=O UXTPWQNJKLFXSB-FMIVXFBMSA-N 0.000 description 1
- LOQMSUDLLHPPHQ-FMIVXFBMSA-N CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc[o]1)(=O)=O Chemical compound CC(C)CN(c(ccc(C(F)(F)F)c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc[o]1)(=O)=O LOQMSUDLLHPPHQ-FMIVXFBMSA-N 0.000 description 1
- NCHAZXLKXQUSJE-UHFFFAOYSA-N CC(C)N(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)N(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1ccc(C)[o]1)(=O)=O NCHAZXLKXQUSJE-UHFFFAOYSA-N 0.000 description 1
- QWTILIQYJYCKQC-UHFFFAOYSA-N CC(C)N(c(cc(C)c(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ncc[s]1)(=O)=O Chemical compound CC(C)N(c(cc(C)c(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ncc[s]1)(=O)=O QWTILIQYJYCKQC-UHFFFAOYSA-N 0.000 description 1
- FTNFWYKWDCDVTN-UHFFFAOYSA-N CC(C)N(c(cc(C)c(C)c1)c1OCc(ccc(C(N1)=NOC1=O)c1)c1OC)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)N(c(cc(C)c(C)c1)c1OCc(ccc(C(N1)=NOC1=O)c1)c1OC)S(c1nc(C)c[s]1)(=O)=O FTNFWYKWDCDVTN-UHFFFAOYSA-N 0.000 description 1
- FNFZHFQRTCHIIN-CSKARUKUSA-N CC(C)N(c(cc(C)c(C)c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S([IH]1=NC(C)=CS1)(=O)=O Chemical compound CC(C)N(c(cc(C)c(C)c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S([IH]1=NC(C)=CS1)(=O)=O FNFZHFQRTCHIIN-CSKARUKUSA-N 0.000 description 1
- CXADZOTVPLQXRS-CSKARUKUSA-N CC(C)N(c(cc(CCC1)c1c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S([IH]1=NC=CS1)(=O)=O Chemical compound CC(C)N(c(cc(CCC1)c1c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S([IH]1=NC=CS1)(=O)=O CXADZOTVPLQXRS-CSKARUKUSA-N 0.000 description 1
- KYTLRJWNWJUXAC-ZHACJKMWSA-N CC(C)N(c(cc(CCC1)c1c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S([IH]1=NC=CS1)(=O)=O Chemical compound CC(C)N(c(cc(CCC1)c1c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S([IH]1=NC=CS1)(=O)=O KYTLRJWNWJUXAC-ZHACJKMWSA-N 0.000 description 1
- JCGZRWAFHTYTRI-UHFFFAOYSA-N CC(C)N(c(ccc(C(F)(F)F)c1)c1OCc(cc1)ccc1-c1nnn[nH]1)[S](c1ccccn1)(=C)(=O)=O Chemical compound CC(C)N(c(ccc(C(F)(F)F)c1)c1OCc(cc1)ccc1-c1nnn[nH]1)[S](c1ccccn1)(=C)(=O)=O JCGZRWAFHTYTRI-UHFFFAOYSA-N 0.000 description 1
- KXNMDMJMLNHPLI-UHFFFAOYSA-N CC(C)N(c(ccc(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc[s]1)(=O)=O Chemical compound CC(C)N(c(ccc(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc[s]1)(=O)=O KXNMDMJMLNHPLI-UHFFFAOYSA-N 0.000 description 1
- OOKCHIGXDLJTJK-BUHFOSPRSA-N CC(C)N(c1cc2ccccc2cc1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)N(c1cc2ccccc2cc1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc(C)[o]1)(=O)=O OOKCHIGXDLJTJK-BUHFOSPRSA-N 0.000 description 1
- QRLTVKDUVCTOHW-UHFFFAOYSA-N CC(CN(c(cc(C)c(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O)=C Chemical compound CC(CN(c(cc(C)c(C)c1)c1OCc(cc1)ccc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O)=C QRLTVKDUVCTOHW-UHFFFAOYSA-N 0.000 description 1
- DDLJQEGSEXJDMR-PKNBQFBNSA-N CCN(c(cc(CCC1)c1c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1nc(C)c[s]1)(=O)=O Chemical compound CCN(c(cc(CCC1)c1c1)c1OCc1c(C)cc(/C=C/C(O)=O)cc1)S(c1nc(C)c[s]1)(=O)=O DDLJQEGSEXJDMR-PKNBQFBNSA-N 0.000 description 1
- ZHPSBMQVLQEIIC-UHFFFAOYSA-N CO[n]1nnc2ccccc12 Chemical compound CO[n]1nnc2ccccc12 ZHPSBMQVLQEIIC-UHFFFAOYSA-N 0.000 description 1
- UDJKGILHJMEKDG-OUKQBFOZSA-N Cc([o]1)ccc1S(N(CC1CC1)c(cc(CCC1)c1c1)c1OCc1ccc(/C=C/C(O)=O)cc1)(=O)=O Chemical compound Cc([o]1)ccc1S(N(CC1CC1)c(cc(CCC1)c1c1)c1OCc1ccc(/C=C/C(O)=O)cc1)(=O)=O UDJKGILHJMEKDG-OUKQBFOZSA-N 0.000 description 1
- UECBIIIPOXTTOK-UHFFFAOYSA-N Cc([o]1)ccc1S(Nc(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1C(OC)=O)(=O)=O Chemical compound Cc([o]1)ccc1S(Nc(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1C(OC)=O)(=O)=O UECBIIIPOXTTOK-UHFFFAOYSA-N 0.000 description 1
- AYYHDPOKMMBQEM-CSKARUKUSA-N Cc1c[s]c(S(N(C)c(cc(CCC2)c2c2)c2OCc2c(C)cc(/C=C/C(O)=O)cc2)(=O)=O)n1 Chemical compound Cc1c[s]c(S(N(C)c(cc(CCC2)c2c2)c2OCc2c(C)cc(/C=C/C(O)=O)cc2)(=O)=O)n1 AYYHDPOKMMBQEM-CSKARUKUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001068498 | 2001-03-12 | ||
| JP2001068498 | 2001-03-12 | ||
| JP2001281569 | 2001-09-17 | ||
| JP2001281569 | 2001-09-17 | ||
| JP2002007760 | 2002-01-16 | ||
| JP2002007760 | 2002-01-16 | ||
| PCT/JP2002/002245 WO2002072564A1 (en) | 2001-03-12 | 2002-03-11 | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003427226A Division JP3741120B2 (ja) | 2001-03-12 | 2003-12-24 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2002072564A1 JPWO2002072564A1 (ja) | 2004-07-02 |
| JP3555620B2 true JP3555620B2 (ja) | 2004-08-18 |
Family
ID=27346214
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002571480A Expired - Fee Related JP3555620B2 (ja) | 2001-03-12 | 2002-03-11 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
| JP2003427226A Expired - Fee Related JP3741120B2 (ja) | 2001-03-12 | 2003-12-24 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
| JP2005245763A Expired - Fee Related JP4432051B2 (ja) | 2001-03-12 | 2005-08-26 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003427226A Expired - Fee Related JP3741120B2 (ja) | 2001-03-12 | 2003-12-24 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
| JP2005245763A Expired - Fee Related JP4432051B2 (ja) | 2001-03-12 | 2005-08-26 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7235667B2 (enExample) |
| EP (2) | EP1612208B1 (enExample) |
| JP (3) | JP3555620B2 (enExample) |
| KR (1) | KR100886854B1 (enExample) |
| CN (1) | CN1294126C (enExample) |
| AT (2) | ATE522513T1 (enExample) |
| AU (1) | AU2002238855B2 (enExample) |
| BR (1) | BR0208027A (enExample) |
| CA (1) | CA2439604C (enExample) |
| CZ (1) | CZ304035B6 (enExample) |
| DE (1) | DE60220255T2 (enExample) |
| DK (2) | DK1369419T3 (enExample) |
| ES (1) | ES2286230T3 (enExample) |
| HU (1) | HU230056B1 (enExample) |
| IL (2) | IL157701A0 (enExample) |
| MX (1) | MXPA03008134A (enExample) |
| NO (1) | NO329682B1 (enExample) |
| NZ (1) | NZ528120A (enExample) |
| PL (1) | PL218750B1 (enExample) |
| PT (2) | PT1612208E (enExample) |
| RU (1) | RU2299202C2 (enExample) |
| TW (1) | TWI317359B (enExample) |
| WO (1) | WO2002072564A1 (enExample) |
| ZA (1) | ZA200306884B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004022549A1 (ja) * | 2002-09-09 | 2005-12-22 | 小野薬品工業株式会社 | ４−メチル−１，３−チアゾール−２−イルスルホニルハライドの製造方法 |
| CN100408570C (zh) * | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
| WO2005000356A1 (ja) * | 2003-06-27 | 2005-01-06 | Ono Pharmaceutical Co., Ltd. | 尿路疾患治療剤 |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| US20080033018A1 (en) * | 2004-07-05 | 2008-02-07 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic Agents For Overactive Bladder |
| JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| JP2009057282A (ja) * | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| BRPI0807942A2 (pt) * | 2007-02-16 | 2014-07-01 | Ono Pharmaceutical Co | Agente terapêutico para distúrbio de excreção urinária |
| ATE554070T1 (de) * | 2007-08-01 | 2012-05-15 | Taisho Pharmaceutical Co Ltd | Hemmer der s1p1-bindung |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| CN102076660B (zh) * | 2008-06-23 | 2014-01-08 | 安斯泰来制药有限公司 | 磺胺化合物或其盐 |
| TW201107309A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
| CN103209960A (zh) * | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
| US20140039004A1 (en) * | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
| CN106660063B (zh) * | 2014-04-30 | 2019-06-18 | 佩纳尔维工业有限公司 | 用于将液体应用于不同形状的盖子上的可编程同心头 |
| SG11201803867TA (en) * | 2015-11-13 | 2018-06-28 | Daewoong Pharmaceutical Co Ltd | Sodium channel blocker |
| RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2419923A1 (de) * | 1973-04-28 | 1974-11-28 | Fujisawa Pharmaceutical Co | Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel |
| JPS5748534B2 (enExample) | 1974-03-04 | 1982-10-16 | ||
| DE2555048A1 (de) * | 1975-12-06 | 1977-06-30 | Pfersee Chem Fab | Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen |
| JPS5293469A (en) | 1976-02-02 | 1977-08-05 | Fuji Photo Film Co Ltd | Method of curing gelatin |
| JPH05293469A (ja) | 1992-04-17 | 1993-11-09 | Toda Constr Co Ltd | 滅菌精製水の製造方法およびその装置 |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| WO2000069465A1 (en) * | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Anticancer agents containing ep1 antagonists as the active ingredient |
| WO2001008674A1 (en) | 1999-07-29 | 2001-02-08 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives and remedies for allodynia |
| US7335776B2 (en) * | 2001-03-14 | 2008-02-26 | Ono Pharmaceutical Co., Ltd. | Remedies for depression containing EP1 antagonist as the active ingredient |
-
2002
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 EP EP05109059A patent/EP1612208B1/en not_active Expired - Lifetime
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
- 2002-03-11 EP EP02705096A patent/EP1369419B1/en not_active Expired - Lifetime
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active Expired - Fee Related
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja not_active Ceased
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
-
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8088802B2 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
| JP7657291B2 (ja) | ジペプチジルペプチダーゼ１の阻害剤として作用するニトリル誘導体及びその使用 | |
| JP5702392B2 (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| KR20080040046A (ko) | 티아졸 유도체 | |
| KR20150018788A (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| WO1998018794A1 (en) | Novel heterocyclic amide compounds and medicinal uses thereof | |
| WO2001055123A1 (en) | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | |
| WO2005053707A1 (ja) | 馬尾神経組織血流増加剤 | |
| IL323168A (en) | Tricyclic compound | |
| WO2006129788A1 (ja) | 神経再生および／または保護剤 | |
| ES2368334T3 (es) | Compuesto de n-fenilarilsulfonamida, composición farmacéutica que comprende el compuesto como principio activo, intermedio sintético para el compuesto y procedimientos para su preparación. | |
| WO2025115896A1 (ja) | Ｅｐ４アゴニスト | |
| CA3285359A1 (en) | Tricyclic compound | |
| WO2024190780A1 (ja) | 三環性化合物を含有する腎疾患の予防及び／又は治療剤 | |
| KR20260038836A (ko) | 삼환성 화합물을 함유하는 신장 질환의 예방 및/또는 치료제 | |
| JPH09136878A (ja) | テトラゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20031127 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040420 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040503 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090521 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090521 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100521 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100521 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100521 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110521 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120521 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120521 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120521 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140521 Year of fee payment: 10 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |